Evidence map›Paper›PMID 25117064›Full record

ArticleThe oncologist2014

Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.

Naoki Hayashi, Ganiraju C Manyam, Ana M Gonzalez-Angulo, Naoki Niikura, Hideko Yamauchi, Seigo Nakamura, Gabriel N Hortobágyi, Keith A Baggerly, Naoto T Ueno

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. BCL11A Expression in Breast Cancer.Current issues in molecular biology · 2023
    Article
  2. Current cancer drug targets · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Proteomics for cancer drug design.Expert review of proteomics · 2019
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Naoki HayashiDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Ganiraju C ManyamDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Ana M Gonzalez-AnguloDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Naoki NiikuraDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Hideko YamauchiDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Seigo NakamuraDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Gabriel N HortobágyiDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Keith A BaggerlyDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan.
Naoto T UenoDepartments of Breast Medical Oncology, Bioinformatics and Computational Biology, and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan; Department of Surgery, Division of Breast Surgical Oncology, The Showa University School of Medicine, Tokyo, Japan nueno@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USShowa University · JPSt. Luke's International Hospital · JP

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancerR01CA123318 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI UENO, NAOTO T. · 2007 to 2012
$1.4M
The PI3K/PTEN/AKT Signal Transduction Cascade in Breast CancerK23CA121994 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GONZALEZ-ANGULO, ANA M. · 2006 to 2010
$680k
Funtional Proteomics and Response to Preoperative Theraphy in Breast CancerR21CA120248 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GONZALEZ-ANGULO, ANA M. · 2006 to 2007
$260k
NCI NIH HHS CA016672NCI NIH HHS CA120248-01NCI NIH HHS CA121994-01NCI NIH HHS CA123318-01NCI NIH HHS K23 CA121994NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA123318NCI NIH HHS R21 CA120248
6 · The paper itself

Abstract

backgroundA biomarker that predicts bone metastasis based on a protein laboratory assay has not been demonstrated. Reverse-phase protein array (RPPA) enables quantification of total and phosphorylated proteins, providing information about their functional status. The aim of this study was to identify bone-metastasis-related markers in patients with primary breast cancer using RPPA analysis. PATIENTS AND

methodsTumor samples were obtained from 169 patients with primary invasive breast carcinoma who underwent surgery. The patients were categorized by whether they developed breast cancer bone metastasis (BCBM) during follow-up. Clinical characteristics and protein expression by RPPA were compared and verified by leave-one-out cross-validation.

resultsLymph node status (p = .023) and expression level of 22 proteins by RPPA were significantly correlated with BCBM in logistic regression analysis. These variables were used to build a logistic regression model. After filtering the variables through a stepwise algorithm, the final model, consisting of 8 proteins and lymph node status, had sensitivity of 30.0%, specificity of 90.5%, positive predictive value of 30.0%, and negative predictive value of 90.5% in the cross-validation. Most of the identified proteins were associated with cell cycle or signal transduction (CDK2, CDKN1A, Rb1, Src, phosphorylated-ribosomal S6 kinase, HER2, BCL11A, and MYH11).

conclusionOur validated model, in which the primary tumor is tested with RPPA, can predict patients who are at low risk of developing BCBM and thus who likely would not benefit from receiving a bisphosphonate in the adjuvant setting. Clinical trials excluding these patients have the potential to clarify the benefit of bisphosphonates in the adjuvant setting.

Indexed as

Protein Array AnalysisAdultAgedAged, 80 and overBiomarkers, TumorBone NeoplasmsBreast NeoplasmsClinical Trials as TopicFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMiddle AgedNeoplasm ProteinsPrognosisRisk FactorsBiomarkers, TumorNeoplasm ProteinsBone metastasisBreast neoplasmPhosphorylated proteinPrediction modelReverse-phase protein array

Identifiers

PMID25117064
PMCPMC4153464
OpenAlexW2129656548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.